Ultragenyx Pharmaceutical vs Telix Pharmaceuticals
RARE and TLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RARE and TLX compare
Telix Pharmaceuticals grew revenue faster over the last twelve months (55.6% versus 15.8% for Ultragenyx Pharmaceutical).
Telix Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −0.89% compared with −71.8% at Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 3 for Telix Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RARE | TLX |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | – |
| Share price | $16.08 | $9.23 |
| Change, 1 year | −52.0% | −5.9% |
| Change, 5 years | −79.7% | – |
| Beta (5Y) | 1.07 | 1.45 |
| Employees | 1,371 | 1,120 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.2× | – |
| FCF yield | −27.9% | – |
| Growth | ||
| Revenue growth (TTM) | 15.8% | 55.6% (better) |
| Revenue growth, 5Y average | 19.9% | – |
| Net income growth (TTM) | – | −121% |
| EPS growth (TTM) | – | −122% |
| Profitability | ||
| Gross margin | – | 53.1% |
| Operating margin | −64.0% | 3.7% (better) |
| Net margin | −71.8% | −0.89% (better) |
| FCF margin | −60.5% | −5.3% (better) |
| Financial health | ||
| Net debt / EBITDA | – | 5.17 |
| Interest coverage | – | 0.7× |
| Current ratio | 1.40 | 2.01 (better) |
| Altman Z-score | −5.73 | – |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 108% | 0.94% |
| Held by insiders | 4.0% | 8.3% |
| Insider net buying, 12 months | −$3.8M | $1.0M (better) |
| Short interest, % of float | 25.0% | – |
Go deeper
- RARE stock overview
- RARE income statement
- RARE valuation and score
- TLX stock overview
- TLX income statement
- TLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.